ANDA 77541, held by Hikma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77541 (Ondansetron Hydrochloride Preservative Free), held by Hikma, was first approved by FDA on Dec 26, 2006, with 7 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron Hydrochloride Preservative FreeEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Aug 16, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 16, 2021 | Supplement 21Labeling · Standard review | Approved | None posted |
| Dec 10, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 10, 2014 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 3, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 3, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 30, 2010 | Supplement 2Labeling | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters